ResearchMoz

Cancer Symptoms Partnering 2007-2013

Current Partnering
Published Date » 2013-10-08
No. Of Pages » 150
The Cancer Symptoms Partnering 2007-2013 report provides understanding and access to the cancer symptoms partnering deals and agreements entered into by the worlds leading healthcare companies.
 
  • Trends in solid tumor cancer partnering deals
  • Top solid tumor cancer deals by value
  • Deals listed by company A-Z, industry sector, stage of development, technology type
 
The Solid Tumor Cancer Partnering 2007-2013 provides understanding and access to the solid tumor cancer partnering deals and agreements entered into by the worlds leading healthcare companies.
 
This report provides details of thelatest cancer symptoms agreements announced in the healthcare sectors, covering:
 
  • Symptoms
  • Oral mucositis
  • Cancer pain
  • Bone
  • Neuropathic
  • Muscular
  • Lymphoedema
  • Alopecia
  • Cachexia
  • Ulcers
  • Dysphagia
  • Tiredness
  • Weight Loss
  • Nausea
  • Vomiting
  • Chemotherapy
  • Radiotherapy

The report provides an analysis of cancer symptoms partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors cancer symptoms technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
 
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.
 
This data driven report contains over 130 links to online copies of actual cancer symptoms deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
 
The initial chapters of this report provide an orientation of cancer symptoms partnering trends.
 
Chapter 1 provides an introduction to the report, whilst 

Chapter 2 provides an overview of the trends in cancer symptoms partnering since 2007, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.
 
Chapter 3 provides an overview of the leading cancer symptoms deals since 2007. Deals are listed by headline value, signed by bigpharma, most active of all pharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
 
Chapter 4 provides a comprehensive directory of cancer symptoms partnering deals signed and announced since 2007. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.
 
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of solid tumor cancer technologies and products.
 
Report scope
 
Cancer Symptoms Partnering 2007-2013 is intended to provide the reader with an in-depth understanding and access to cancer symptoms trends and structure of deals entered into by leading companies worldwide.
 
This data driven report includes:
 
  • Trends in cancer symptoms dealmaking in the biopharma industry since 2007
  • Access to summary headline, upfront, milestone and royalty data
  • Access to over 130 cancer symptoms contract documents
  • The leading cancer symptoms deals by value since 2007
 
In Cancer Symptoms Partnering 2007-2013, the available deals are listed by:
 
  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Company A-Z
  • Industry sector
  • Stage of development at signing
  • Deal component type
  • Technology type
 
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Cancer Symptoms Partnering 2007-2013 provides the reader with the following key benefits:
 
  • In-depth understanding of cancer symptoms deal trends since 2007
  • Access to summary headline, upfront, milestone and royalty data
  • Comprehensive access to over 130 actual cancer symptoms deals entered into by the world’s biopharma companies since 2007
  • Insight into key deal terms included in contracts, where disclosed
  • Understand the key deal terms companies have agreed in deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies
TABLE OF CONTENT

Executive Summary
 
Chapter 1 – Introduction
 
Chapter 2 – Trends in cancer symptoms partnering
2.1. Introduction
2.2. Cancer symptoms partnering over the years
2.3. Bigpharma cancer symptoms dealmaking activity
2.4. Cancer symptoms partnering by deal type
2.5. Cancer symptoms partnering industry sector
2.6. Cancer symptoms partnering by stage of development
2.7. Cancer symptoms partnering by technology type
2.8. Disclosed financial deal terms for cancer symptoms partnering
2.8.1 Cancer symptoms headline values
2.8.2 Cancer symptoms upfront payments
2.8.3 Cancer symptoms milestone payments
2.8.4 Cancer symptoms royalty rates
 
Chapter 3 – Leading cancer symptoms deals
3.1. Introduction
3.2. Top cancer symptoms deals by value
3.3. Top cancer symptoms deals involving bigpharma
 
Chapter 4 – Dealmaking directory
4.1. Introduction
4.2. Company A-Z
4.3. By deal type
Asset purchase
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Manufacturing
Marketing
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Termination
4.4. By industry sector
Academic
Bigpharma
Biotech
Drug delivery
Medical device
Diagnostic
Generic pharma
Government
Non-profit
Pharmaceutical
Research tools
Services
Specialty pharma
4.5. By stage of development
Discovery
Pre-clinical
Phase I
Phase II
Phase III
Registration
Marketed
4.6. By technology type
Analysis
Animal models
Assays
Bioinformatics
Biological compounds
Biomarkers
Biomaterials
Cell culture
Cell therapy
Clinical testing
Diagnostic - companion
Devices
Diagnostics
Discovery tools
DNA probes
Drug delivery
Enabling technology
Epigenetics
Equipment
Facilities
Gene therapy
Genomics
Imaging
Industrial chemicals
In vitro models
Monoclonal antibodies
Nanotechnology
Oligonucleotide
Peptides
Personalised medicine
Processes
Proteomics
Radio/Chemo-therapy
Recombinant DNA
Research services
Research supplies
RNA therapeutics
Screening
Small molecules
Stem cells
Vaccines
 
Chapter 5 – Partnering resource center
5.1. Online partnering
5.2. Partnering events
5.3. Further reading on dealmaking
 
Appendices
 
Appendix 1 – Deal type definitions
 
About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering
Order Form – Reports

List of Tables

NA

List of Figures

 
Figure 1: Cancer symptoms partnering since 2007
Figure 2: Bigpharma – top 50 – Cancer symptoms deals 2007 to 2013
Figure 3: Bigpharma cancer symptoms deal frequency – 2007 to 2013
Figure 4: Cancer symptoms partnering by deal type since 2007
Figure 5: Cancer symptoms partnering by industry sector since 2007
Figure 6: Cancer symptoms partnering by stage of development since 2007
Figure 7: Cancer symptoms partnering by technology type since 2007
Figure 8: Cancer symptoms deals with a headline value
Figure 9: Cancer symptoms deals with upfront payment values
Figure 10: Cancer symptoms deals with milestone payments
Figure 11: Cancer symptoms deals with royalty rates, %
Figure 12: Top cancer symptoms deals by value since 2007
Figure 13: Top cancer symptoms deals signed by bigpharma value since 2007
Figure 14: Online partnering resources
Figure 15: Forthcoming partnering events
Figure 16: Deal type definitions

Upcoming Reports:

Automotive Paints Market - Global Industry Analysis, Market Share, Size, Growth, Trends And Forecast, 2012 - 2018
By - Transparency Market Research
Automotive paint plays an important role in the protection of automotives against acid rains, UVrays, oxidization and corrosion. It is one of the primary features that a customer sees and is attracted towards. Most people judge the performance and durability of the respective vehicle by the quality and durability of its paint. Automotive paints have low VOC & high solid content.  They are easy to apply and are clean and wear resistant. Companies are also using paints such as high-solids, powder, water-based, and radiation-cure paints which have low or no volatile...
Oral Care Products Market - Global Industry Size, Market Share, Trends, Analysis, And Forecasts 2012 - 2018
By - Transparency Market Research
The oral care product market is growing rapidly due to technological advancements and introduction of fresh products in the market. Dentifrice and toothbrush are mainly responsible for the primary growth of this market. Rise in consciousness about maintaining oral care is likely to increase the growth rate in the near future. There are a variety of oral care products available in market manufactured by different companies.  This research report analyzes the oral care product market on the basis of its segments and four major geographies. This research study...
Outage Management System (OMS) - Global Industry Analysis, Size, Share, Trends, Analysis, Growth And Forecast, 2013 - 2019
By - Transparency Market Research
OMS is a tool for identifying and improving the efficiency of restoration and communication with customers. OMS integrates with systems such as Supervisory Control and Data Acquisition System (SCADA), Distribution Automation (DA) System, Automatic Meter Reading (AMR), Advanced Metering Infrastructure (AMI), Customer Information System (CIS), Interactive Voice Response System (IVR) and Geographic Information System (GIS) for outage management.  OMS helps in analyzing outage events, calculate restoration time, and providing reliable outage report. The outage management functions...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

India is Facing a Cancer Crisis
Apr 15, 2014  
India is currently facing a cancer crisis – reports a recent research carried out at the King’s college London, in collaboration with the Tata Memorial Cancer Centre, Mumbai.  The reasons estimated for this crisis comprise of increasing rates of smoking, unequal access to proper treatment and belated diagnosis.  Every year, India witnesses around one...
Microparticle Tags to Check Counterfeit Goods Invented
Apr 14, 2014  
Researchers from the Massachusetts Institute of Technology have invented a new set of microparticles that can easily be read by smartphones and establish the authenticity of currency, electronic items and luxury goods.  This strategy is among those countless measures taken by big brands and companies to label their legitimate products in order to stop illegal copies of the...
USFDA Approves Lupins Generic Diabetic Drug
Apr 10, 2014  
The United States Food and Drugs Administration (USFDA) has finally approved Lupin Pharmaceuticals Inc (LPI), the American subsidiary of Indian drug manufacturers Lupin Ltd, to sell Pioglitazone Tablets in the U.S market. The approval has been granted first for fiscal 2015.  Pioglitazone is a generic medicine used for managing diabetes and is a version of Actos tablets...
Infrared Sensors can Soon Be Used to Develop Night-Vision Lenses - A New Discovery Confirms
Apr 8, 2014  
People who fear the dark may soon have a reason to rejoice – an infrared sensor that can eventually be used for mechanizing night-vision lenses has been developed. This effectively means that one can also see through dark with the help of these lenses.  This technology seems possible all due to graphene, a layer of tightly packed carbon atoms that has allowed the creation of...
Ontarios thanks Sustainable Development Technology Canada for Clean Tech Ecosystem Movements
Apr 8, 2014  
Sustainable Development Technology Canada has leveraged an extra $2.2 billion in funding from project partners that also includes global clean technology companies.  Sustainable Development Technology Canada (SDTC) is energizing and evolving the development and demonstration of a clean technology ecosystem. They are the vital contributors to the prominent concentration of clean...